APUS
Apimeds Pharmaceuticals US, Inc
Drug Manufacturers - Specialty & Generic
Market Cap$16M
5Y Perf.-16.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
APUS vs SLRX
Revenue, margins, valuation, and 5-year total return — side by side.
SLRX
Salarius Pharmaceuticals, Inc.
Biotechnology
Market Cap$698K
5Y Perf.-93.3%
APUS vs SLRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | APUS | SLRX |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $16M | $698K |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-6.00B | $-5M |
| Total Debt | $7.77B | $222K |
| Cash & Equiv. | $1.64B | $2M |
APUS vs SLRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
APUS
SLRX
| Stock | May 25 | May 26 | Return |
|---|---|---|---|
| Apimeds Pharmaceuti… (APUS) | 100 | 84.0 | -16.0% |
| Salarius Pharmaceut… (SLRX) | 100 | 6.7 | -93.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: APUS vs SLRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: APUS leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Salarius Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
APUS
Apimeds Pharmaceuticals US, Inc
The Income Pick
APUS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.82
- EPS growth 50.0%
- -33.2% 10Y total return vs SLRX's -100.0%
Best for: income & stability and growth exposure
SLRX
Salarius Pharmaceuticals, Inc.
The Growth Leader
SLRX is the clearest fit if your priority is growth and quality.
- -0.2% revenue growth vs APUS's -52.7%
- 5.2% margin vs APUS's -0.0%
Best for: growth and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SLRX | -0.2% revenue growth vs APUS's -52.7% |
| Quality / Margins | SLRX | 5.2% margin vs APUS's -0.0% |
| Stability / Safety | APUS | Beta 0.82 vs SLRX's 1.10, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | APUS | -33.2% vs SLRX's -93.1% |
| Efficiency (ROA) | APUS | -14.6% ROA vs SLRX's -82.1% |
APUS vs SLRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2020
APUS vs SLRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAPUSLAGGINGSLRX
SLRXSalarius Pharmaceutic…
1leads
APUSApimeds Pharmaceutica…
4leads
6 Total Categories
CATEGORYLEADERvs SLRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SLRX1/1
Valuation MetricsMultiples, price ratios, and targets
APUS2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
APUS5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
APUS5/6
Risk & VolatilityBeta, volatility, and downside exposure
APUS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SLRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
APUS and SLRX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | APUSApimeds Pharmaceu… | SLRXSalarius Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$12M | -$5M |
| Net IncomeAfter-tax profit | -$6.0B | -$5M |
| Free Cash FlowCash after capex | -$9M | -$4M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +62.6% | +84.1% |
SLRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
APUS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | APUSApimeds Pharmaceu… | SLRXSalarius Pharmace… |
|---|---|---|
| Market CapShares × price | $16M | $697,790 |
| Enterprise ValueMkt cap + debt − cash | $6.2B | -$2M |
| Trailing P/EPrice ÷ TTM EPS | -2.67x | -0.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.03x |
| Price / FCFMarket cap ÷ FCF | — | — |
APUS leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
APUS leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
APUS delivers a -15.7% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-118 for SLRX. APUS carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to SLRX's 0.15x. On the Piotroski fundamental quality scale (0–9), APUS scores 4/9 vs SLRX's 3/9, reflecting mixed financial health.
| Metric | APUSApimeds Pharmaceu… | SLRXSalarius Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -15.7% | -117.8% |
| ROA (TTM)Return on assets | -14.6% | -82.1% |
| ROICReturn on invested capital | -0.0% | — |
| ROCEReturn on capital employed | -0.0% | -168.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.05x | 0.15x |
| Net DebtTotal debt minus cash | $6.1B | -$2M |
| Cash & Equiv.Liquid assets | $1.6B | $2M |
| Total DebtShort + long-term debt | $7.8B | $221,866 |
| Interest CoverageEBIT ÷ Interest expense | -42.09x | — |
APUS leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
APUS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in APUS five years ago would be worth $6,682 today (with dividends reinvested), compared to $2 for SLRX. Over the past 12 months, APUS leads with a -33.2% total return vs SLRX's -93.1%. The 3-year compound annual growth rate (CAGR) favors APUS at -12.6% vs SLRX's -85.8% — a key indicator of consistent wealth creation.
| Metric | APUSApimeds Pharmaceu… | SLRXSalarius Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -12.0% | +13.3% |
| 1-Year ReturnPast 12 months | -33.2% | -93.1% |
| 3-Year ReturnCumulative with dividends | -33.2% | -99.7% |
| 5-Year ReturnCumulative with dividends | -33.2% | -100.0% |
| 10-Year ReturnCumulative with dividends | -33.2% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -12.6% | -85.8% |
APUS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
APUS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
APUS is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than SLRX's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APUS currently trades 24.6% from its 52-week high vs SLRX's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | APUSApimeds Pharmaceu… | SLRXSalarius Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 1.10x |
| 52-Week HighHighest price in past year | $5.97 | $34.65 |
| 52-Week LowLowest price in past year | $0.95 | $0.52 |
| % of 52W HighCurrent price vs 52-week peak | +24.6% | +2.1% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 47.6 |
| Avg Volume (50D)Average daily shares traded | 198K | 79K |
APUS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | APUSApimeds Pharmaceu… | SLRXSalarius Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
APUS leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). SLRX leads in 1 (Income & Cash Flow).
Best OverallApimeds Pharmaceuticals US,… (APUS)Leads 4 of 6 categories
Loading custom metrics...
APUS vs SLRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — APUS or SLRX?
Over the past 5 years, Apimeds Pharmaceuticals US, Inc (APUS) delivered a total return of -33.
2%, compared to -100. 0% for Salarius Pharmaceuticals, Inc. (SLRX). Over 10 years, the gap is even starker: APUS returned -33. 2% versus SLRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — APUS or SLRX?
By beta (market sensitivity over 5 years), Apimeds Pharmaceuticals US, Inc (APUS) is the lower-risk stock at 0.
82β versus Salarius Pharmaceuticals, Inc. 's 1. 10β — meaning SLRX is approximately 34% more volatile than APUS relative to the S&P 500. On balance sheet safety, Apimeds Pharmaceuticals US, Inc (APUS) carries a lower debt/equity ratio of 5% versus 15% for Salarius Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — APUS or SLRX?
On earnings-per-share growth, the picture is similar: Apimeds Pharmaceuticals US, Inc grew EPS 50.
0% year-over-year, compared to -1522. 7% for Salarius Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — APUS or SLRX?
Apimeds Pharmaceuticals US, Inc (APUS) is the more profitable company, earning 0.
0% net margin versus 0. 0% for Salarius Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APUS leads at 0. 0% versus 0. 0% for SLRX. At the gross margin level — before operating expenses — APUS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — APUS or SLRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is APUS or SLRX better for a retirement portfolio?
For long-horizon retirement investors, Apimeds Pharmaceuticals US, Inc (APUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
82)). Both have compounded well over 10 years (APUS: -33. 2%, SLRX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between APUS and SLRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.